钠-葡萄糖协同转运蛋白2抑制剂用于间充质-上皮转化抑制剂诱导的水肿
Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema.
作者信息
Oyakawa Takuya, Miura Keita, Muraoka Nao, Iida Kei, Fujita Ayano, Naito Tateaki, Takahashi Toshiaki
机构信息
Division of Cardio-oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Division of Thoracic oncology, Shizuoka Cancer Center, Shizuoka, Japan.
出版信息
Thorac Cancer. 2025 Jan;16(2):e15509. doi: 10.1111/1759-7714.15509. Epub 2024 Dec 13.
The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on mesenchymal-epithelial transition factor (MET) inhibitor-induced edema remain unclear. In a patient with tepotinib-induced edema and an N-terminal pro-brain natriuretic peptide (NTproBNP) level ≥ 300 pg/mL, the addition of empagliflozin to loop diuretics reduced the edema. This suggests that empagliflozin may be a treatment option for MET inhibitor-induced edema.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对间充质-上皮转化因子（MET）抑制剂所致水肿的影响尚不清楚。在一名因服用替泊替尼出现水肿且N末端脑钠肽前体（NTproBNP）水平≥300 pg/mL的患者中，在袢利尿剂基础上加用恩格列净减轻了水肿。这表明恩格列净可能是治疗MET抑制剂所致水肿的一种选择。
Zotero 插件